TEVA (Teva Pharmaceutical Industries) Cyclically Adjusted PS Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TEVA Teva Pharmaceutical Industries Ltd TEVA
47 GF Score
Price $40.06
GF Value $18.61
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Teva Pharmaceutical Industries Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Teva Pharmaceutical Industries  (NYSE:TEVA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Teva Pharmaceutical Industries Cyclically Adjusted PS Ratio Related Terms


Teva Pharmaceutical Industries Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Teva Pharmaceutical Industries's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teva Pharmaceutical Industries Cyclically Adjusted PS Ratio Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 0.40 0.48 1.06 1.58

Teva Pharmaceutical Industries Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.82 1.00 1.57 1.52 1.72

TEVA vs ZTS, UTHR, VTRS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teva Pharmaceutical Industries Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's Cyclically Adjusted PS Ratio falls into.


TEVA
47GF Score
Teva Pharmaceutical Industries Ltd TEVA
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Teva Pharmaceutical Industries Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Teva Pharmaceutical Industries's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Teva Pharmaceutical Industries's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=3.623/333.9520*333.9520
=3.623

Current CPI (Jun. 2026) = 333.9520.

Teva Pharmaceutical Industries Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 5.688 241.428 7.868
201612 6.380 241.432 8.825
201703 5.631 243.801 7.713
201706 5.687 244.955 7.753
201709 5.527 246.819 7.478
201712 5.331 246.524 7.222
201803 4.961 249.554 6.639
201806 4.580 251.989 6.070
201809 4.446 252.439 5.882
201812 4.256 251.233 5.657
201903 3.822 254.202 5.021
201906 3.821 256.143 4.982
201909 3.770 256.759 4.903
201912 4.084 256.974 5.307
202003 3.927 258.115 5.081
202006 3.533 257.797 4.577
202009 3.660 260.280 4.696
202012 4.082 260.474 5.234
202103 3.535 264.877 4.457
202106 3.552 271.696 4.366
202109 3.507 274.310 4.270
202112 3.732 278.802 4.470
202203 3.297 287.504 3.830
202206 3.371 296.311 3.799
202209 3.157 296.808 3.552
202212 3.540 296.797 3.983
202303 3.247 301.836 3.592
202306 3.425 305.109 3.749
202309 3.361 307.789 3.647
202312 3.982 306.746 4.335
202403 3.450 312.332 3.689
202406 3.659 314.175 3.889
202409 3.843 315.301 4.070
202412 3.733 315.605 3.950
202503 3.317 319.799 3.464
202506 3.702 322.561 3.833
202509 3.859 324.800 3.968
202512 4.053 324.054 4.177
202603 3.378 330.213 3.416
202606 3.623 333.952 3.623

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Teva Pharmaceutical Industries (TEVA) Overvalued in 2026?

Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued. The current stock price of $40.06 is trading 115.3% above its estimated GF Value™ of $18.61. GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.

Key valuation signals for TEVA:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $18.61 vs. price of $40.06 (115.3% above fair value)
  • GF Score™: 47/100 with 6 warning signs

No single metric tells the full story. See the TEVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Teva Pharmaceutical Industries Business Description

Address 124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
47GF Score

Get the complete analysis for TEVA

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$40.06
Price
$18.61
GF Value